Gender-based blood transcriptomes and interactomes in multiple sclerosis: Involvement of SP1 dependent gene transcription

Journal of Autoimmunity

Volumn 38, Issue 2-3, 2012, Pages

  Menon, Ramesh ^a,b   Di Dario, Marco ^a,b   Cordiglieri, Chiara ^a,b   Musio, Silvia ^b   La Mantia, Loredana ^b   Milanese, Clara ^b   Di Stefano, Anna Luisa ^c   Crabbio, Massimo ^c   Franciotta, Diego ^c   Bergamaschi, Roberto ^c   Pedotti, Rosetta ^b   Medico, Enzo ^d   Farina, Cinthia ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Gender; Multiple sclerosis; SP1 transcription factor; Systems biology; Transcriptomics

Indexed keywords

3',3' N XYLENYLBIS(DAUNORUBICIN); ANDROGEN RECEPTOR; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERACTOME; RNA; TRANSCRIPTION FACTOR SP1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; ANIMALS; CLUSTER ANALYSIS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MULTIPLE SCLEROSIS; REPRODUCIBILITY OF RESULTS; SEX FACTORS; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84858749570     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.11.004     Document Type: Article

References (54)

1. Zuvich R.L., McCauley J.L., Pericak-Vance M.A., Haines J.L. Genetics and pathogenesis of multiple sclerosis. Semin Immunol 2009, 21:328-333.
2. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann Neurol 2009, 65:239-248.
3. Tremlett H., Zhao Y., Devonshire V. UBC Neurologists. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol 2009, 256:374-381.
4. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
5. Comabella M., Martin R. Genomics in multiple sclerosis-current state and future directions. J Neuroimmunol 2007, 187:1-8.
6. Sawcer S., Ban M., Maranian M., Yeo T.W., Compston A., Kirby A., et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005, 77:454-467.
7. International Multiple Sclerosis Genetics Consortium, Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851-862.
8. Wiendl H., Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 2009, 72:1008-1015.
9. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
10. Saeed A.I., Bhagabati N.K., Braisted J.C., Liang W., Sharov V., Howe E.A., et al. TM4 microarray software suite. Methods Enzymol 2006, 411:134-193.
11. Li C., Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001, 98:31-36.
12. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121.
13. Sebastiani P., Xie H., Ramoni M.F. Bayesian analysis of comparative microarray experiments by model averaging. Bayesian Anal 2006, 1:707-732.
14. Carmona-Saez P., Chagoyen M., Tirado F., Carazo J.M., Pascual-Montano A. GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol 2007, 8:R3.
15. Hu Z., Snitkin E.S., DeLisi C. VisANT: an integrative framework for networks in systems biology. Brief Bioinform 2008, 9:317-325.
16. Ramanathan M., Weinstock-Guttman B., Nguyen L.T., Badgett D., Miller C., Patrick K., et al. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol 2001, 116:213-219.
17. Bomprezzi R., Ringner M., Kim S., Bittner M.L., Khan J., Chen Y., et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet 2003, 12:2191-2199.
18. Achiron A., Gurevich M., Friedman N., Kaminski N., Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 2004, 55:410-417.
19. Iglesias A.H., Camelo S., Hwang D., Villanueva R., Stephanopoulos G., Dangond F. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J Neuroimmunol 2004, 150:163-177.
20. Booth D.R., Arthur A.T., Teutsch S.M., Bye C., Rubio J., Armati P.J., et al. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J Mol Med 2005, 83:822-830.
21. Achiron A., Gurevich M., Snir Y., Segal E., Mandel M. Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis. Clin Exp Immunol 2007, 149:235-242.
22. Gurevich M., Tuller T., Rubinstein U., Or-Bach R., Achiron A. Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med Genomics 2009, 2:46.
23. Gandhi K.S., McKay F.C., Cox M., Riveros C., Armstrong N., Heard R.N., et al. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet 2010, 19:2134-2143.
24. Achiron A., Gurevich M. Gender effects in relapsing-remitting multiple sclerosis: correlation between clinical variables and gene expression molecular pathways. J Neurol Sci 2009, 286:47-53.
25. Berchtold N.C., Cribbs D.H., Coleman P.D., Rogers J., Head E., Kim R., et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci USA 2008, 105:15605-15610.
26. Simunovic F., Yi M., Wang Y., Stephens R., Sonntag K.C. Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS One 2010, 5:e8856.
27. Maes O.C., Xu S., Yu B., Chertkow H.M., Wang E., Schipper H.M. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 2007, 28:1795-1809.
28. Whitney A.R., Diehn M., Popper S.J., Alizadeh A.A., Boldrick J.C., Relman D.A., et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003, 100:1896-1901.
29. Karlovich C., Duchateau-Nguyen G., Johnson A., McLoughlin P., Navarro M., Fleurbaey C., et al. A longitudinal study of gene expression in healthy individuals. BMC Med Genomics 2009, 2:33.
30. Tomassini V., Pozzilli C. Sex hormones, brain damage and clinical course of multiple sclerosis. J Neurol Sci 2009, 286:35-39.
31. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009, 33:3-11.
32. Urdinguio R.G., Sanchez-Mut J.V., Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009, 8:1056-1072.
33. Tao Q., Robertson K.D. Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 2003, 109:53-63.
34. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002, 2:725-734.
35. Ghosh S., Hayden M.S. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008, 8:837-848.
36. Yan J., Greer J.M. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol Disord Drug Targets 2008, 7:536-557.
37. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 164:10-21.
38. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001, 293:1653-1657.
39. Rokhlin O.W., Glover R.B., Guseva N.V., Taghiyev A.F., Kohlgraf K.G., Cohen M.B. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 2006, 4:113-123.
40. Altuwaijri S., Chuang K.H., Lai K.P., Lai J.J., Lin H.Y., Young F.M., et al. Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells. Mol Endocrinol 2009, 23:444-453.
41. Tomassini V., Onesti E., Mainero C., Giugni E., Paolillo A., Salvetti M., et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 2005, 76:272-275.
42. Sicotte N.L., Giesser B.S., Tandon V., Klutch R., Steiner B., Drain A.E., et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol 2007, 64:683-688.
43. Riveros C., Mellor D., Gandhi K.S., McKay F.C., Cox M.B., Berretta R., et al. A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis. PLoS One 2010, 5:e14176.
44. Xie X., Lu J., Kulbokas E.J., Golub T.R., Mootha V., Lindblad-Toh K., et al. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 2005, 434:338-345.
45. Cakouros D., Cockerill P.N., Bert A.G., Mital R., Roberts D.C., Shannon M.F. A NF-kappa B/Sp1 region is essential for chromatin remodeling and correct transcription of a human granulocyte-macrophage colony-stimulating factor transgene. J Immunol 2001, 167:302-310.
46. Lu S., Jenster G., Epner D.E. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 2000, 14:753-760.
47. Liu S., Wu L.C., Pang J., Santhanam R., Schwind S., Wu Y.Z., et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010, 17:333-347.
48. Chang J.T., Nevins J.R. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006, 22:2926-2933.
49. Chiang S.Y., Azizkhan J.C., Beerman T.A. A comparison of DNA-binding drugs as inhibitors of E2F1- and Sp1-DNA complexes and associated gene expression. Biochemistry 1998, 37:3109-3115.
50. Martin B., Vaquero A., Priebe W., Portugal J. Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro. Nucleic Acids Res 1999, 27:3402-3409.
51. Mansilla S., Portugal J. Sp1 transcription factor as a target for anthracyclines: effects on gene transcription. Biochimie 2008, 90:976-987.
52. Chaires J.B., Leng F., Przewloka T., Fokt I., Ling Y.H., Perez-Soler R., et al. Structure-based design of a new bisintercalating anthracycline antibiotic. J Med Chem 1997, 40:261-266.
53. Leng F., Priebe W., Chaires J.B. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. Biochemistry 1998, 37:1743-1753.
54. Hu G.G., Shui X., Leng F., Priebe W., Chaires J.B., Williams L.D. Structure of a DNA-bisdaunomycin complex. Biochemistry 1997, 36:5940-5946.